Previous close | 1.4000 |
Open | 1.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 395.00 |
Expiry date | 2024-06-14 |
Day's range | 1.4000 - 1.4000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
On May 31, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 4,600 shares of the company.
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is the leading gene therapy stock to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
On May 29, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 2,280 shares of the company.